DaVita Inc. (NYSE:DVA) Shares Purchased by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. increased its holdings in shares of DaVita Inc. (NYSE:DVA) by 36.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,827 shares of the company’s stock after purchasing an additional 6,896 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $4,234,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Transcendent Capital Group LLC acquired a new stake in shares of DaVita during the 3rd quarter worth about $25,000. Atria Investments Inc boosted its holdings in DaVita by 12.3% during the 3rd quarter. Atria Investments Inc now owns 2,897 shares of the company’s stock valued at $475,000 after acquiring an additional 317 shares during the period. CWA Asset Management Group LLC acquired a new position in DaVita in the 3rd quarter valued at about $444,000. Financial Strategies Group Inc. grew its position in DaVita by 19.2% in the 3rd quarter. Financial Strategies Group Inc. now owns 3,135 shares of the company’s stock valued at $507,000 after acquiring an additional 504 shares in the last quarter. Finally, QRG Capital Management Inc. grew its position in DaVita by 5.0% in the 3rd quarter. QRG Capital Management Inc. now owns 4,577 shares of the company’s stock valued at $750,000 after acquiring an additional 216 shares in the last quarter. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Activity at DaVita

In related news, COO Michael David Staffieri sold 9,539 shares of the company’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the transaction, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other DaVita news, COO Michael David Staffieri sold 9,539 shares of the business’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $150.03, for a total value of $1,431,136.17. Following the completion of the sale, the chief operating officer now owns 241,945 shares in the company, valued at approximately $36,299,008.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Javier Rodriguez sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $165.05, for a total value of $8,252,500.00. Following the completion of the sale, the chief executive officer now owns 837,835 shares of the company’s stock, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 165,625 shares of company stock valued at $26,238,297 over the last three months. 2.00% of the stock is owned by corporate insiders.

DaVita Stock Performance

Shares of DaVita stock opened at $154.48 on Tuesday. DaVita Inc. has a one year low of $84.64 and a one year high of $168.50. The company has a market cap of $12.67 billion, a PE ratio of 16.66, a P/E/G ratio of 0.84 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37. The business has a 50-day simple moving average of $157.22 and a 200-day simple moving average of $147.05.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.85 earnings per share. On average, equities research analysts forecast that DaVita Inc. will post 9.71 EPS for the current fiscal year.

Analyst Ratings Changes

DVA has been the subject of several research reports. TD Cowen lifted their target price on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Barclays lifted their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Bank of America lifted their target price on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a research report on Wednesday, August 7th. UBS Group lifted their target price on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Finally, Truist Financial lifted their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.